lemma health

Explore Treatments See How It Works Learn Sign in

Dupixent
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Eric L Simpson, Bolanle Akinlade, Marius Ardeleanu

Comment

•

None participants

•

2017

•

47 citations

Key insights related to Dupixent from this study:

Dupilumab significantly improves signs and symptoms of moderate-to-severe atopic dermatitis, including skin lesions, itching, and quality of life compared to placebo. In clinical trials, 60-70% of patients achieved a 75% improvement in disease severity scores after 16 weeks of treatment.

What is this paper about?

nan
What populations did the authors study?

nan
What did the authors find?

nan
What conclusions can we draw?

nan

Did this article interest you?

As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.

Group of men

Ready for better skin health?

At Lemma Health, we provide evidence-based skin care. Access providers in all 50 states. Receive your medications delivered.